MESALAZINE (PENTASA(R)) IN PREGNANCY

We analysed the outcome of II pregnancies in women treated for inflamm atory bowel disease with mesalazine (Pentasa(R)) during part of or thr oughout pregnancy. There were 9 healthy babies, one spontaneous aborti on (the woman had an uterine malformation) and one infant with multipl e malformations (but the mother was not treated with mesalazine during organogenesis). Because of the relatively small number of pregnancies exposed to mesalazine (Pentasa(R)) in this study, these data need to be confirmed by other studies.